Why Is Micro-Cap AIM ImmunoTech Stock Surging?

All NewsJuly 28, 2025

AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent